Commentary
Video
Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer
Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center, discusses findings from an analysis of the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) compared with physician’s choice of chemotherapy in patients with hormone receptor (HR)–positive, HER2-low or -ultralow metastatic breast cancer who were stratified by pace of disease progression on prior endocrine therapy plus a CDK4/6 inhibitor.
